The increasing number of HER2 positive breast cancer patients being treated in the neoadjuvant setting gives rise to the need to accurately assess HER2 status on the CNB material that often is the only tissue available before treatment in these patients. This evidence concerns the gene ERBB2 and breast carcinoma.